Slide 1: LP-300 in EGFR Exon 21 L858R Mutated Patients
wnarmonic LP-300 in EGFR Exon 21 L858R Mutated Patients HARMONIC™ Phase 2 Trial | FDA Type C Meeting Results | May 2026 Study Sponsored by @>lantempharma
Slide 2: Forward-Looking Statements
wiharmonic Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, s
Slide 3: A Focused Trial for LP-300 in EGFR Exon 21 L858R
A Focused Trial for LP-300 in EGFR Exon 21Lassr 9 ermMonic High-Need 7 i Defined Population Compelling Early Signal EGFR exon 21 L858R mutation - found in ~40% of all Preliminary HARMONIC™ data (n=31, data cutoff May EGFR-mutant NSCLC cases across diverse and global 2026) show an 8.4-month mPFS and
Slide 4: Overview of the LP-300 Molecule
w/narmonic Overview of the LP-300 Molecule ° ‘ I LP-300 (Dimesna Established Safety Track Record LAVA Pw ( ) os Small molecule | Phase 2 i 10+ Phase 1, 2 & 3 clinical trials Receptor tyrosine kinase inhibition ] ' saoete 1,000+ Covalently inhibits EGFR, ALK, MET, ROS1 via cysteine adducts individual
Slide 5: LP-300 - Mechanism of Action
wnarmonic —LP-300 - Mechanism of Action LOE id cetera §=6LP-300's multimodal MoA resensitizes NSCLC to chemo Pathways in Never ‘Smokers Mt © EGF, TGF-alpha, etc ° LP-300 mas Engages with TKI Receptors via Cysteine Modification A-B. LP-300 adduct at Cys1235 Cys1156 C. Molecular surface of ALK with th
Slide 6: Never & Non-Smoker NSCLC: A Distinct & Underserved Disease
wharmonic Never & Non-Smoker NSCLC: A Distinct & Underserved Disease 400-500K Top 10 40% 0 new never-smoker NSCLC cancer worldwide if classified of NSCLC EGFR mutations _ therapies specifically developed or cases per year globally as a standalone disease occur in Exon 21 - L858R labeled for this pop
Slide 7: EGFR Mutation Landscape in NSCLC
harmonic EGFR Mutation Others Landscape in NSCLC ZC Exon 21 L858R Why L858R is a High-Unmet-Need Subgroup Point mutation in kinase domain — lower TKI binding affinity Inferior outcomes on osimertinib vs. exon 19 deletions in multiple trials Shorter recurrence-free survival post-surgery (14.7 vs. 28.
Slide 8: Target Lesion Decreased in Over 70% of Evaluable L858R Patients
wharmonic Target Lesion Decreased in Over 70% of Evaluable L858R Patients Percent change in cancer lesion size over time Percent change in cancer lesion size by patient = 107-003 = 110-004 ~ 110-011 ~ 303-007 ~ 505-002 Best Response ICR MPO EPR BSD Subject ~ 109-008 = 110-007 ~ 301-001 ~ 304.002 ~ 5
Slide 9: The HARMONIC Trial — Study Design
wharmonic The HARMONIC™ Trial — Study Design Part 1 (ciscontinued enrollment) Study Arms (21 03y cycle) . . . "56 Investigating LP-300 in combination 6 Gia dedi Stratification (gender) => Pensa sn) with pemetrexed and carboplatin in 5. G85 esi | neaaeeenliaat | After 6 es : : = oyeles never smoker p
Slide 10: FDA Type C Meeting Outcome — A Key De-Risking Milestone
wharmonic FDA Type C Meeting Outcome — A Key De-Risking Milestone What is an FDA Type C Meeting? Outcome: May 2026 A written guidance interaction allowing sponsors to request "FDA raised no objections a formal FDA feedback on ongoing clinical programs — specifically on protocol design, endpoints, an
Slide 11: Safety Profile — LP-300 vs. Current Post-TKI Standard of Care
wharmonic — Safety Profile — LP-300 vs. Current Post-TKI Standard of Care LP-300 is positioned as a potential best-in-tolerability option in post-TKI L858R NSCLC. It adds no clinically meaningful toxicity beyond the carboplatin/pemetrexed backbone - a critical advantage in heavily pretreated patient
Slide 12: Competitive Landscape — Post-TKI EGFR-Mutant NSCLC
wharmonic Competitive Landscape — Post-TKI EGFR-Mutant NSCLC LP-300 + Carboplatin + Pemetrexed 8.4 mo* Grade 1-2 only; no new added (HARMONIC™ — L858R enriched) 43%* (6.2-NE) || toxicities to that of chemotherapies; NCT05456256 8.9 mo* 3% serious TRAES Fea ial eure ee Tease 9.7mo 23% serious TRAEs:
Slide 13: Global Trial Footprint — Strategic Geography
wharmonic Global Trial Footprint — Strategic Geography United States Enrolling Japan 15-20% of NSCLC in never-smokers, Clinical Sites + Fairfax, VA + Fountain Valley, CA “Dallas, TX - Philadelphia, PA - Los Angeles, CA - Beverly Hills, CA 32.8% of NSCLC in never-smokers, Clinical Sites + National Ca
Slide 14: Path Forward — LP-300 in EGFR Exon 21 L858R NSCLC
wharmonic Path Forward — LP-300 in EGFR Exon 21 L858R NSCLC Now FDA Type C successful outcome Enrollment enrichment for L858R initiated Single-arm design transition underway Partnership & Collaboration Opportunities 2026* Additional clinical data update expected Expanded L858R cohort data disclosed
Slide 15: Investment Highlights
Investment Highlights wh LP-300 in EGFR Exon 21 L858R NSCLC armonic ( ) 1 Large, Defined Market ( ) 2 Regulatory Clarity ( ) 3 Compelling Early Data 400-S00K patients/year globally with no Successful FDA Type C response — no 8.4-month mPFS in L858R cohort; 6+ month dedicated therapy. L858R subgroup:
Slide 16: Data Disclaimers and Key References
wnarmonic Data Disclaimers + HARMONIC™ data cutoff: May 11, 2026 (n=31). All data preliminary and subject to change. + Cross-trial comparisons with MARIPOSA-2 (amivantamab) are not head-to-head studies and should be interpreted with caution. + Retrospective analyses from Phase 3 trial DMS32212R (Bio